| abstract |
Disclosed are prodrugs of cytotoxic anthracyclines (such as doxorubicin) and other therapeutic agents that are selectively cleaved and activated by fibroblast activation protein (FAP). Prodrugs are useful for targeted delivery of cytotoxic agents and other drugs to FAP-expressing tissues including cancer (eg, solid tumors). Also provided are pharmaceutical compounds, including prodrugs, and methods of using the prodrugs to treat disorders characterized by FAP upregulation, such as cancer, fibrosis, and inflammation. |